Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ajanta Beats Q2 Expectations

Ajanta Net Profit Slides 7% But Analysts Remain Positive

Executive Summary

India’s Ajanta has reported a 7% drop in second-quarter net profit with its African branded generics remaining a problem area. However, US sales climbed by nearly 40% and analysts remain positive on the company’s outlook, buoyed by a beat on revenue estimates.

You may also be interested in...



Ajanta’s Profit Slides 6% In Fourth Quarter But US Sales Rocket

Ajanta Pharma announced a 6% fall in net profit for the final financial quarter, hit by a further drop in its Africa business – but US sales soared nearly 80%.

Ajanta set to focus on US generics market

Ajanta Pharma’s managing director Yogesh Agrawal has revealed that going forward, the US generics business “will be a key focus market” for the Indian firm. He also reiterated the company’s previous plans to focus on the branded generics business in India and also in Emerging Markets (Generics bulletin, 11 May 2018, page 8).

 

Cadila Healthcare Merges Four Subsidiaries

India’s Cadila Healthcare, which has been suffering on the earnings front, is amalgamating four subsidiaries under its roof to reduce overheads from managing separate entities and avoid duplication of efforts after posting weak second-quarter earnings.

Topics

UsernamePublicRestriction

Register

GB149408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel